v1
Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study.
Identifier:nobleid.org/w1/20260515/6F2F0AF8
Type:Journal Article
0 views
Embeddable Badge
[](https://nobleid.org/work/w1/20260515/6F2F0AF8)
Bibliometric Analysis
Impact metrics, research fronts, co-authorship networks →
Authors & Claims